Skip to main content

Table 2 Measures reported in the included studies

From: A review of the psychometric performance of the EQ-5D in people with urinary incontinence

  Generic measures Other measures used
Author(s), Year Descriptive system Tariff used Direct valuation Condition-specific HRQoL measures used Clinical measures used Qualitative questions
Ternent et al, 2009 [20] EQ-5D Not stated None KHQ None None
PGI
Ismail et al, 2009 [16] EQ-5D Not stated None KHQ 1 hr pad test None
Leakage episodes
Pad usage
Rinne et al, 2008 [22] EQ-5D Not stated None UISS Cough stress test Satisfaction with operation.
DIS 24-hr pad
VAS
IIQ-7
UDI-6
Haywood et al, 2008 [7] EQ-5D States general population utility weights. None I-QoL (index and individual domains) SSI Subjective treatment benefit assessed by patient.
Incontinence episodes per week at baseline
Monz et al, 2007 [12] EQ-5D Not stated EQ-VAS I-QOL UI severity (Sandvik Index) Bother (4 point scale)
UI subtype (S/UIQ)
Kobelt et al, 2006 [21] EQ-5D Reference suggests UK tariff used. None None Incontinence grade  
Median number of episodes per day
Dumville et al, 2006 [17] EQ-5D UK tariff None None Objective cure* (negative 1 hr pad test) Subjective cure* (perfectly happy / pleased) to spend rest of life with current urinary symptoms
SF-36
*(reported in related clinical paper)
Currie et al, 2006 [10] EQ-5D Not stated None None None None
SF-36
Monz et al, 2005 [13] EQ-5D Not stated None I-QOL Sandvik index (severity based on frequency and leakage amount) Bothersomeness and limitations of daily activities
Manca et al, 2003 [18] EQ-5D UK tariff    Objective cure (based on negative pad test and negative cystometry)  
SF-36
Subjective cure (based on BFLUTS)
Kobelt, 1997 [14] EQ-5D UK tariff. EQ-VAS [15]   Frequency of micturitions and involuntary urine loss (combined measure)  
SF-36
Hawthorn, 2009 [2] EQ-5D EQ-5D: UK tariff     
SF-6D
AQoL SF-6D: Not stated
AQoL-8 (derived from
AQoL &
AQoL) AQoL-8: community TTO
HUI-3 (deciles)
Tincello et al, 2010 [19] EQ-5D UK tariff None None Episodes per week None
Saarni, 2006 [9] EQ-5D EQ-5D: UK tariff   None None None
15-D
15-D Finnish valuation set
Noble et al, 2002 [11] EQ-5D Not stated None I-PSS which includes a quality of life score. Maximum flow rate  
Post void residual urine
Number of successful procedures (based on I-PSS and maximum urinary flow)
Mihaylova et al, 2010 [23] EQ-5D UK tariff    Number of leaks during 7 days  
Donovan et al, 1997 [8] EQ-5D (UK, Denmark and Netherland only, N=359) Not reported   ICSQol (ICSmale)   
SF-36 (UK only, N=205)
  1. AQoL=Assessment of Quality of Life, BFLUTS=Bristol Female Lower Urinary Tract Symptoms Questionnaire, DIS= Detrusor instability scores, EQ-VAS=Visual analogue scale which accompanies the EQ-5D descriptive system, HUI-3=Health Utilities Index Mark 3, ICSQol=International Continence Society – Benign Prostatic Hyperplasia study Quality of Life Instrument, IIQ-7=Incontinence Impact Questionnaire-short form, I-PSS = International Prostate Symptom Score, I-QOL=Incontinence specific Quality of life Questionnaire, KHQ=King’s Health Questionnaire, PGI = Patient Generated Index, SF-36=Medical outcomes study 36-Item Short-Form Health Survey , SF-6D= Classification for describing health derived from a selection of SF-36 items, SSI=Symptom Severity Index, S/UIQ=Stress and Urge Incontinence Questionnaire, UDI-6=Urogenital Distress Inventory-short form, UI=Urinary incontinence, UISS=Urinary Incontinence Severity Score, VAS=Visual Analogue Scale, 15-D=Fifteen dimension generic instrument.